Labcorp® announced the availability of therascreen®KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen. Labcorp’s oncology platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, helping to pioneer scientific breakthroughs like the KRAS companion diagnostic to identify patients eligible for cutting-edge targeted therapies. During the last 25 years, Labcorp has played a significant role in launching hallmark testing options for the treatment of cancer. The company remains committed to further developing companion diagnostics and precision medicines. This new offering adds to its growing portfolio of tests that specialize in more personalized care, leading to more specific treatment choices. In addition to single marker tests, Labcorp offers full panels of testing powered by advanced next generation-sequencing (NGS) technology for complete profiling of a patient’s unique tumor, including mutations in KRAS.